

AUSTRALIAN PATENT GRANTED FOR hTERT

- **Australian Patent No. 2015218188 granted to BARD1 by IP Australia**
- **Provides patent protection for hTERT in Australia until 2035**

Melbourne, Australia, 15 March 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or **Company**) announces that it has been granted Australian patent number 2015218188 entitled 'Method of Detecting Cancer'.

Australian patent 2015218188 covers the use of the Company's hTERT antibody to resolve inconclusive cytology and detect malignant cells.

The hTERT patent family PCT/AU2015/050060 now has granted patents in Australia, China, Europe, Japan and the USA, and additional pending patents in Israel and the US (continuation), providing intellectual property protection for the hTERT test in these countries.

The hTERT test is an immunocytochemistry (ICC) assay that detects hTERT, a component of telomerase, which is increased in most human epithelial cancers. The test is used as an adjunct to urine cytology, assisting in the diagnosis of bladder cancer.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch

CEO

E leearne@bard1.com

M +61 400 414 416

Dr Geoff Cumming

Non-Executive Chairman

E geoff.cumming@bard1.com

M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising best-in-class diagnostic solutions for healthcare professionals and patients. The cancer diagnostics portfolio includes the commercialised hTERT test used as an adjunct to urine cytology testing and diagnostic tests in development for ovarian, breast, lung, prostate and pancreatic cancers. For more information on BARD1, see www.bard1.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.